Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB) : a randomised, phase III, trial

Tools
- Tools
+ Tools

Fernando, Indrajit N., Bowden, Sarah J., Herring, Kathryn, Brookes, Cassandra L., Ahmed, Ikhlaaq, Marshall, Andrea, Grieve, Robert J., Churn, Mark, Spooner, David, Latief, Talaat N. et al.
(2020) Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB) : a randomised, phase III, trial. Radiotherapy and Oncology, 142 . pp. 52-61. doi:10.1016/j.radonc.2019.10.014 ISSN 0167-8140.

[img]
Preview
PDF
WRAP-synchronous-versus-sequential-chemo-radiotherapy-patients-breast-Dunn-2019.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (1263Kb) | Preview
Official URL: https://doi.org/10.1016/j.radonc.2019.10.014

Request Changes to record.

Abstract

Background
The optimal sequence of adjuvant chemotherapy and radiotherapy for breast cancer is unknown. SECRAB assesses whether local control can be improved without increased toxicity.

Methods
SECRAB was a prospective, open-label, multi-centre, phase III trial comparing synchronous to sequential chemo-radiotherapy, conducted in 48 UK centres. Patients with invasive, early stage breast cancer were eligible. Randomisation (performed using random permuted block assignment) was stratified by centre, axillary surgery, chemotherapy, and radiotherapy boost. Permitted chemotherapy regimens included CMF and anthracycline-CMF. Synchronous radiotherapy was administered between cycles two and three for CMF or five and six for anthracycline-CMF. Sequential radiotherapy was delivered on chemotherapy completion. Radiotherapy schedules included 40 Gy/15F over three weeks, and 50 Gy/25F over five weeks. The primary outcome was local recurrence at five and ten years, defined as time to local recurrence, and analysed by intention to treat.

ClinicalTrials.gov NCT00003893.

Findings
Between 02-July-1998 and 25-March-2004, 2297 patients were recruited (1150 synchronous and 1146 sequential). Baseline characteristics were balanced. With 10.2 years median follow-up, the ten-year local recurrence rates were 4.6% and 7.1% in the synchronous and sequential arms respectively (hazard ratio (HR) 0.62; 95% confidence interval (CI): 0.43–0.90; p = 0.012). In a planned sub-group analysis of anthracycline-CMF, the ten-year local recurrence rates difference were 3.5% versus 6.7% respectively (HR 0.48 95% CI: 0.26–0.88; p = 0.018). There was no significant difference in overall or disease-free survival. 24% of patients on the synchronous arm suffered moderate/severe acute skin reactions compared to 15% on the sequential arm (p < 0.0001). There were no significant differences in late adverse effects apart from telangiectasia (p = 0.03).

Interpretation
Synchronous chemo-radiotherapy significantly improved local recurrence rates. This was delivered with an acceptable increase in acute toxicity. The greatest benefit of synchronous chemo-radiation was in patients treated with anthracycline-CMF.

Item Type: Journal Article
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
SWORD Depositor: Library Publications Router
Library of Congress Subject Headings (LCSH): Breast -- Cancer, Breast -- Cancer -- Chemotherapy, Breast -- Cancer -- Radiotherapy, Breast -- Cancer -- Research, Clinical trials
Journal or Publication Title: Radiotherapy and Oncology
Publisher: Elsevier
ISSN: 0167-8140
Official Date: 1 January 2020
Dates:
DateEvent
1 January 2020Published
27 November 2019Available
20 October 2019Accepted
Volume: 142
Page Range: pp. 52-61
DOI: 10.1016/j.radonc.2019.10.014
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Date of first compliant deposit: 4 December 2019
Date of first compliant Open Access: 4 December 2019
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
CRUK/98/001Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
Related URLs:
  • Other

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us